Hoth Therapeutics announced positive preclinical results for its therapy GDNF, which reprograms liver fat metabolism at the genetic level to treat metabolic-associated fatty liver disease (MAFLD) and obesity. The therapy significantly reduces Srebf1, a gene driving fat production, and increases Pparα, which regulates fat burning, outperforming existing treatments like semaglutide. Unlike current therapies focused mainly on weight loss, GDNF targets the root causes of fat accumulation in the liver, potentially offering a disease-modifying treatment. Hoth plans further preclinical studies and clinical development to advance this novel metabolic therapy.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
